– Odd stocks anticipated to start buying and selling on Nasdaq on April 20, 2026 following trade of all American Depositary Stocks (ADSs)
– ADS holders will obtain one unusual percentage indexed on Nasdaq for each and every ADS held
– Simplified list construction supposed to allow enhanced intensity and breadth of possession
COPENHAGEN, Denmark, April 08, 2026 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) these days introduced that it plans to listing its unusual stocks immediately on Nasdaq, efficient on the opening of buying and selling on April 20, 2026.
As a part of the transition to an instantaneous list of unusual stocks on The Nasdaq World Choose Marketplace, all exceptional ADSs will probably be exchanged for unusual stocks. Each and every ADS recently eligible for buying and selling will probably be exchanged for one unusual percentage, which will probably be indexed and start buying and selling on The Nasdaq World Choose Marketplace underneath the Corporate’s current ticker image “ASND” on April 20, 2026.
“As we transform into a leading global biopharma company, we believe a direct listing of our ordinary shares will broaden access to global investment in Ascendis,” stated Scott T. Smith, Leader Monetary Officer of Ascendis Pharma. “In addition, we believe a direct listing may also facilitate inclusion in certain equity indexes, which could result in further enhanced institutional ownership and trading liquidity for ASND shares.”
About Ascendis Pharma A/SAscendis Pharma is an international biopharmaceutical corporate thinking about making use of our cutting edge TransCon era platform to make a significant distinction for sufferers. Guided through our core values of Sufferers, Science, and Hobby, and following our set of rules for product innovation, we observe TransCon to broaden new remedies that display best-in-class doable to handle unmet clinical wishes. Ascendis is headquartered in Copenhagen, Denmark, and has further amenities in Europe and the USA. Please seek advice from ascendispharma.com to be told extra.
Ahead-Taking a look Statements This press liberate accommodates forward-looking statements that contain really extensive dangers and uncertainties. All statements, instead of statements of ancient info, integrated on this press liberate relating to Ascendis’ long run operations, plans and goals of control are forward-looking statements inside the that means of Phase 27A of the Securities Act of 1933, as amended, and Phase 21E of the Securities Trade Act of 1934, as amended. Examples of such statements come with, however don’t seem to be restricted to, statements with regards to (i) the pondered timing and implementation of the trade of ADSs for unusual stocks, (ii) the pondered list and buying and selling of unusual stocks on The Nasdaq World Choose Marketplace, and (iii) the predicted advantages of the direct list of unusual stocks. Ascendis would possibly not if truth be told succeed in the plans, perform the intentions or meet the expectancies or projections disclosed within the forward-looking statements and also you must no longer position undue reliance on those forward-looking statements. Precise effects or occasions may just range materially from the plans, intentions, expectancies and projections disclosed within the forward-looking statements. Quite a lot of necessary elements may just motive exact effects or occasions to range materially from the forward-looking statements that Ascendis makes, together with the next: dangers that the trade of ADSs for unusual stocks might not be finished at the expected timeline or in any respect; dangers associated with the eligibility of the unusual stocks for clearance and protecting in The Depository Believe Corporate device; the chance that unusual stocks might not be licensed for list on The Nasdaq World Choose Marketplace, or that list could also be not on time or topic to stipulations; dangers that buying and selling in unusual stocks on Nasdaq could also be much less liquid or lead to other buying and selling dynamics than buying and selling in ADSs; doable hostile tax penalties to ADS holders in reference to the trade of ADSs for unusual stocks; and dangers associated with the affect of the trade of ADSs for unusual stocks at the Corporate’s different exceptional securities. For an extra description of the dangers and uncertainties that might motive exact effects to range from the ones expressed in those forward-looking statements, in addition to dangers with regards to Ascendis’ trade typically, see Ascendis’ Annual Record on Shape 20-F filed with the U.S. Securities and Trade Fee (SEC) on February 11, 2026, and Ascendis’ different long run studies filed with, or submitted to, the SEC. Ahead-looking statements don’t replicate the possible affect of any long run licensing, collaborations, acquisitions, mergers, tendencies, joint ventures, or investments that Ascendis would possibly input into or make. Ascendis does no longer think any legal responsibility to replace any forward-looking statements, excluding as required through regulation.
Ascendis, Ascendis Pharma, the Ascendis Pharma emblem, and TransCon are emblems owned through the Ascendis Pharma workforce.© April 2026 Ascendis Pharma A/S.
Investor Contacts:Media Touch:Chad FugereMelinda BakerAscendis PharmaAscendis Pharma+1 (650) 519-7494+1 (650) 709-8875
